Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trialYoung‐Suk Lim, Seungbong Han, Ming‐Lung Yu et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 23
The impact of pylorus preservation on the development of nonalcoholic fatty liver disease after pancreaticoduodenectomy: A historical cohort studyDongsub Jeon, Jonggi Choi, Song Cheol Kim et al.|Journal of Hepato-Biliary-Pancreatic Sciences|2022Cited by 12
One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatmentTai‐Chung Tseng, Jia‐Horng Kao, Jonggi Choi et al.|Hepatology International|2021Cited by 11